Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-GD2-800CW first-in-human imaging study in pediatric neuroblastoma
NL-OMON59888Phase 2Suspended
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Nov 2025
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Anti-GD2-800CW in neuroblastoma, sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Anti-GD2-800CW related adverse events and Tumor-to-background ratio. Started Nov 2025; status: suspended.
02
Drugs
Anti-GD2-800CW
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NL-OMON59888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59888.